Gaebel W
Psychiatrische Klinik, Heinrich-Heine-Universität, Rheinische Landes- und Hochschulklinik, Düsseldorf, Germany.
Int Clin Psychopharmacol. 1995 Jan;9 Suppl 5:11-6. doi: 10.1097/00004850-199501005-00003.
Neuroleptic maintenance medication is clearly effective for relapse prevention in schizophrenia. However, besides benefits for the majority of patients, there are also failures and/or risks for some patients (e.g. tardive dyskinesia). Since the risk-benefit ratio is often difficult to predict in the individual case, this has stimulated the search for modifications and alternatives to maintenance treatment. In particular, neuroleptic low-dose treatment strategies compare favorably with standard-dose treatment concerning relapse prevention and side effects. Alternatively, based on prodromal symptoms preceding a relapse, early intervention, intermittent neuroleptic treatment strategies have been developed. However, all recently completed controlled 2 year studies have not confirmed this strategy to be as effective as maintenance treatment in preventing relapse. Therefore, for the majority of patients intermittent treatment cannot be recommended.